How can public health authorities such as the FAMHP, in cooperation with the FPS Public Health, the RIZIV-INAMI and the KCE, involve the patient more proactively and make the patient more central through the entire development cycle of innovative drugs? Come and find out everything at the third symposium of the FAMHP, where patients are central, on Tuesday, December 10.
Patients and patient associations, sponsors of clinical trials (academic and commercial), researchers and doctors.
- Recent initiatives of the FAMHP about proactive participation of patient representatives and patient experts in the evaluation of clinical trials and preliminary requests for scientific advice.
- Involvement of the patient in the development of the Informed Consent Form (ICF) within the framework of the new European regulation on clinical trials.
- Human body materials and biobank legislation in Belgium: what does the patient need to know?
- Presentation of the KCE report on the involvement of the patient in the preparation of policy for research in health care and experiences in the evaluation of the publicly financed clinical trials.
- The role of the FAMHP, EMA and RIZIV-INAMI in the (early) approval and (timely) reimbursement of innovative drugs and treatments: guideline for the patient.
- Introduction of the new “Patient Expert Committee (PEC)” initiative in Belgium: what does it mean for the patient?
The symposium will take place on Tuesday morning, December 10, in the Pacheco Center, Pachecolaan 13, 1000 BRUSSELS. The symposium starts at 9:20 a.m. and will end at 1:00 p.m. followed by a sandwich lunch. The speakers will present in their native language with simultaneous translation (NL/FR) provided.
Attendance is free, but you are required to register. More information and the final programme will be available soon. Note the date in your schedule now or register now.